We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HEIA:EURONEXT AMSTERDAMHeineken NV Analysis

Data as of 2026-09-02 - not real-time

€72.02

Latest Price

3/10Risk

Risk Level: Low

Executive Summary

The moving-average structure behind Heineken N.V. is neutral at €72.02, with no clear ordering between short and long averages. Across the trailing 30 sessions it lost 7.3%. Relative strength is 39.3 — approaching oversold — and the MACD signal is bearish. The recent range runs from support at €71.14 up to resistance at €79.90.
Multiples put this in undervalued territory at a P/E of 17.6. The average analyst target implies 23.7% above today's level. Revenue is growing at 4.7% on a 7.7% profit margin. The 2.64% dividend yield looks covered by current payout levels.
Risk scores 3 out of 10, which is low for this asset class. With 30-day volatility of 20.7%, a beta of 0.08 and a maximum drawdown of 19.5%, the drawdown profile is forgiving relative to most of the market. The wider market backdrop reads extreme greed at 91 on the fear-greed composite.
The horizons diverge: hold near-term but buy on a long view, at 5/10 conviction over the longer horizon.

Top Market Events

Heineken N.V. reports the progress of transactions under its current share buyback programme Amsterdam, 29 June 2026 -...Heineken stock reflects a cautious outlook as brewers highlight challenging consumer sentiment and eHeineken N.V. shares on Euronext Amsterdam traded slightly higher on 06/01/2026 as the Dutch brewer

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 4/10

Key Factors

  • Trading above the 200-day average of 70.93
  • MACD momentum is negative
  • 30-day price change of -7.3%

Medium Term

1–3 years
Positive
Model confidence: 5/10

Key Factors

  • Trading above the 200-day average of 70.93
  • Analyst targets imply +23.7% versus the current price
  • MACD momentum is negative

Long Term

> 3 years
Positive
Model confidence: 5/10

Key Factors

  • Analyst targets imply +23.7% versus the current price
  • P/E ratio of 17.6
  • Dividend yield of 2.64%

Key Metrics & Analysis

Financial Health

Revenue Growth4.70%
Profit Margin7.70%
P/E Ratio17.6
ROE12.13%
ROA3.99%
Debt/Equity95.11
P/B Ratio2.1
Op. Cash Flow€5.8B
Free Cash Flow€3.0B

Technical Analysis

TrendNeutral
RSI39.3
Support€71.14
Resistance€79.90
MA 20€73.49
MA 50€75.30
MA 200€70.93
MACDBearish
VolumeDecreasing
Fear & Greed Index91.43

Valuation

Fair Value€51.92
Target Price€89.09
Upside/Downside23.71%
GradeUndervalued
TypeBlend
Dividend Yield2.64%

Risk Assessment

Beta0.08
Volatility20.70%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.